It can be said that pharmaceutical companies face a 'new era.' in the coming years. Old strategies will not produce the same results. A wave of generic competition is poised to affect most brands. Drug companies have had to cut research budgets, leading to a dearth of new products on the market. This means there is very little margin for error in the pricing decision.
Drug pricing is one of the key levers that determine the profitability of a drug company. Premium pricing of a new drug helps cover the high cost of innovation and helps run a profitable enterprise. But the recent onslaught of generics, as well as shrinking government and corporate healthcare budgets, is threatening the time-tested models, leading to higher pricing pressures for pharmaceutical and biotech companies in the coming years. In this environment, executives in these companies and the consultants who service them need better information to make the most profitable decisions.
Kalorama Information's Drug Pricing and Reimbursement Strategies: Preparing for the Coming Generic Onslaught provides considerable detail on the this all-important area of pharmaceutical marketing strategy. The guide describes pricing strategies for specific results, including:
Drug pricing and reimbursement also differs widely across the globe due to the huge disparity in economic situations of various countries, and this global report addresses the pricing environments in:
License Note: Kalorama Information's listed default price on its information products reflects a single user license only. Purchasing a global site license (entire company) permits multiple individuals in the company to benefit from this resource.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook